Ambros Therapeutics announced its launch with a $125 million financing and plans to run a Phase 3 trial of neridronate, an agent licensed from Italy’s Abiogen Pharma, to treat complex regional pain syndrome (CRPS) in the U.S. The company named Vivek Ramaswamy among its backers and investors include RA Capital and Enavate Sciences. Ambros is taking an existing, regionally approved drug and repositioning it for a high-unmet-need chronic pain indication in the U.S., aiming to leverage the licensed asset to accelerate a registrational pathway. STAT reported the launch and investor list, noting the company’s immediate focus on an NDA-enabling Phase 3 readout. If the Phase 3 succeeds, Ambros would bypass much of discovery-stage risk but face the typical US access and payer hurdles for pain drugs. The deal-backed launch underscores investor appetite for specialty pain plays built on de-risked, geographically validated assets.